



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/854,694	05/15/2001	Bo Skaaning Jensen	2815-0159P	8119

2292 7590 04/24/2002

BIRCH STEWART KOLASCH & BIRCH  
PO BOX 747  
FALLS CHURCH, VA 22040-0747

EXAMINER

ROBINSON, BINTA M

ART UNIT PAPER NUMBER

1625

DATE MAILED: 04/24/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/854,694

Applicant(s)

JENSEN ET AL.

Examiner

Binta M. Robinson

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-20-24-25 is/are pending in the application.
- 4a) Of the above claim(s) 3,7,10-14 and 17-20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,2,4-6,8,9,16,24 and 25 is/are rejected.
- 7) ☒ Claim(s) 15 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_.

**Detailed Action**


Claim 24 at paper no. 6 is withdrawn in light of applicant's amendment at paper no. 7/B. The 112, first paragraph rejection of claims 21-24 are rendered moot in light of applicant's amendment at paper no. 7/B.

**(Old rejections)**


1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 2, 4, 5, 6, 8, 9, 15, 16, 21, 23-25 are rejected under 35 U. S. C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

 A. In claims 1, 2, 4, 5, 6, 8, 9, and 16, the terms "mono- or polycyclic groups, mono or poly heterocyclic groups, aralkyl groups, or a hetero-alkyl groups" are indefinite.

These terms are so broad as to render the claim meaningless.

 B. In claim 21, there is no reference to an "effective amount" of this pharmaceutical composition being delivered to a host in need thereof.

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

*100p*

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1625

Claims 1, 2, 4, 5, 6, 8, and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Morisawa et. al. (See Reference N) Morisawa et. al. teaches the instant compound Propanedioic acid, (4-fluorophenyl)(3-pyridinylmethyl)-,diethyl ester. At pages 1-111, see the instant compound.

**( new rejections)**

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 2, 4,5, 6, 8, 9, 15, 16, 24-25 are rejected under 35 U. S. C. 112, first paragraph, because the specification, does not reasonably provide enablement for R1 or R2 equal to all mono- or polycyclic groups, mono or poly heterocyclic groups, aralkyl groups, or a hetero-alkyl groups which may be optionally substituted as claimed in claim 1 or R3 and R4 coming together to form an unsaturated or a partially or completely saturated mono- or polycyclic group, or a mono- or poly-heterocyclic group. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention in scope with these claims. The claims as recited are broader than the scope of enablement. The specification lacks direction or guidance for placing all of the alleged products in the possession of the public without inviting more than routine experimentation. The applicant is referred to In re Wands, 858 f. 2d 731, 737, 8 USPQ 2d 1400, 1404 (Fed. Cir. 1988) which includes

the incorporation of the 8 Wands factors recited in Ex parte Foreman 230 USPQ 546 (Bd. Of App. And Inter 1986).

Claim 24 is rejected under 35 U. S. C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. There is no reasonable assurance that these compounds will have all of the alleged properties or have the applicants supplied the data. The applicant is referred to In re Fouche 169 USPQ 429 ccpa, 1971, MPEP 716.02 B. The applicant is referred to In re Wands, 858 f. 2d 731, 737, 8 USPQ 2d 1400, 1404 (Fed. Cir. 1988) which includes the incorporation of the 8 factors recited in Ex parte Foreman 230 USPQ 546 (Bd. Of App. And Inter. 1986).

*Keep*

Claim 25 is rejected under 35 U. S. C. 112, first paragraph, because the specification, does not reasonably provide enablement for the method of treating all of the various respiratory disorders claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The claims as recited are broader than the scope of enablement. The applicant is referred to In re Wands, 858 f. 2d 731, 737, 8 USPQ 2d 1400, 1404 (Fed. Cir. 1988) which includes the incorporation of the 8 factors recited in Ex parte Foreman 230 USPQ 546 (Bd. Of App. And Inter 1986).

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is

Art Unit: 1625

"undue". These factors include 1) the breadth of the claims, 2) the nature of the invention, 3) the state of the prior art, 4) the level of one of ordinary skill, 5) the level of predictability in the art 6) the amount of direction provided by the inventor 7) the existence of working examples, and 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. In *re Wands*, 858 F. 2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

In terms of the first Wands factor of breadth, one of the moieties that R1 is claimed as is a to all mono- or polycyclic groups, mono or poly heterocyclic groups, aralkyl groups, or a hetero-alkyl groups which may be optionally substituted as claimed in claim 1, yet only thienyl and optionally substituted phenyl rings are exemplified in working examples. The R2 moiety is claimed as a heterocyclic ring to all mono- or polycyclic groups, mono or poly heterocyclic groups, aralkyl groups, or a hetero-alkyl groups which may be optionally substituted as claimed in claim 1 yet only Thienyl, oxazole, and pyridyl are only tested in the specification. Radicals R3 and R4 coming together to form an unsaturated or a partially or completely saturated mono- or polycyclic group, or a mono- or poly-heterocyclic group is claimed, yet, no working examples with rings are tested. R3 and R4 can only be CO<sub>2</sub>Et, CONH<sub>2</sub>, CN, or CO<sub>2</sub>tBu in the working examples in the specification. In terms of the fifth Wands factor, the specification discloses that all of the test compounds showed activity at a final concentration of about 10 microMoles, and that these compounds therefore are SK/IK/BK channel modulating agents. However, the specification does not go into how effective these compounds are in modulating these channels. In terms of the sixth

Art Unit: 1625

Wands factor, the amount of direction provided by the inventor is poor, because the inventor test compounds with very limited Markush groupings, whereas R1-R4 encompass much larger Markush groupings. In terms of the 8<sup>th</sup> Wands factors, undue experimentation would be required to make or use the invention based on the content of the disclosure due to the breadth of the claims, the level of predictability in the art of the invention, and the poor amount of direction provided by the inventor. Taking the above factors into consideration, it is not seen where the instant claim is enabled by the instant application.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

✓ A. In claim 1, line 25, page 41, the phrase "may optionally be" is indefinite.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Binta M. Robinson whose telephone number is (703) 306-5437. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman can be reached on (703)308-4698. The fax phone numbers for the organization where this application or proceeding is assigned are (703)308-7922 for regular communications and (703)308-7922 for After Final communications.


Art Unit: 1625

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0193.

Binta Robinson



April 23, 2002



**ALAN L. ROTMAN**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**